HOOKIPA Pharma (HOOK) Stock Price, News & Analysis

Company Overview

HOOKIPA Pharma Inc. is a clinical-stage biotechnology company focused on the development of virus-based immunotherapies and vaccines. The company operates two complementary platform technologies—an engineered Modified Vaccinia Ankara (MVA) vector and an arenavirus vector system—designed to stimulate both humoral and cellular immune responses. By combining these platforms, HOOKIPA aims to address infectious diseases and drive novel immuno-oncology treatments.

In the infectious disease arena, HOOKIPA’s pipeline includes prophylactic vaccine candidates targeting pathogens such as cytomegalovirus (CMV) in transplant settings and other viral threats. The arenavirus-based platform is leveraged to induce strong T-cell responses against persistent viruses, while the MVA vector is optimized for broader antibody and T-cell activation. Preclinical and early clinical data have underscored the potential of these approaches to provide durable immunity with a favorable safety profile.

Beyond infectious disease, HOOKIPA is advancing immuno-oncology programs that employ its vector systems to generate anti-tumor immune responses. These candidates are engineered to present tumor-associated antigens, aiming to recruit and expand cytotoxic T cells within the tumor microenvironment. This dual focus on both prophylactic and therapeutic indications reflects the company’s strategy to harness its platform versatility across multiple disease areas.

Founded in 2016, HOOKIPA Pharma is headquartered in Vienna, Austria, with a U.S. subsidiary based in New York. The company’s leadership team comprises experienced executives and scientific founders who have previously held senior roles in biopharmaceutical research and development. HOOKIPA continues to collaborate with academic institutions and industry partners to advance its clinical pipeline and expand the reach of its novel immunotherapy platforms.

Key Stats

• Today's Range: $0.89 to $0.92
• 50-Day Range: $0.82 to $0.95
• 52-Week Range: $0.72 to $4.32
• Volume: 21,106 shs
• Average Volume: 106,613 shs
• Market Capitalization: $11.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.50
• Consensus Rating: Hold

HOOKIPA Pharma Stock Analysis - MarketRank™

HOOKIPA Pharma scored higher than 59% of companies evaluated by MarketBeat, and ranked 429th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

HOOKIPA Pharma has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Upside Potential

HOOKIPA Pharma has a consensus price target of $4.50, representing about 389.1% upside from its current price of $0.92.

Amount of Analyst Coverage

HOOKIPA Pharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for HOOKIPA Pharma are expected to decrease in the coming year, from ($1.75) to ($2.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of HOOKIPA Pharma is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of HOOKIPA Pharma is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

HOOKIPA Pharma has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.11% of the outstanding shares of HOOKIPA Pharma have been sold short.

Short Interest Ratio / Days to Cover

HOOKIPA Pharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in HOOKIPA Pharma has recently decreased by 16.17%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

HOOKIPA Pharma does not currently pay a dividend.

Dividend Growth

HOOKIPA Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.11% of the outstanding shares of HOOKIPA Pharma have been sold short.

Short Interest Ratio / Days to Cover

HOOKIPA Pharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in HOOKIPA Pharma has recently decreased by 16.17%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, HOOKIPA Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $39,362.00 in company stock.

Percentage Held by Insiders

Only 3.30% of the stock of HOOKIPA Pharma is held by insiders.

Percentage Held by Institutions

63.88% of the stock of HOOKIPA Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HOOK Stock Analysis - Frequently Asked Questions

How have HOOK shares performed this year?

HOOKIPA Pharma's stock was trading at $2.01 at the beginning of 2025. Since then, HOOK shares have decreased by 54.2% and is now trading at $0.92.

How were HOOKIPA Pharma's earnings last quarter?

HOOKIPA Pharma Inc. (NASDAQ:HOOK) issued its earnings results on Thursday, May, 15th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by $0.62. HOOKIPA Pharma had a negative net margin of 785.66% and a negative trailing twelve-month return on equity of 120.09%.

When did HOOKIPA Pharma's stock split?

Shares of HOOKIPA Pharma reverse split before market open on Wednesday, July 10th 2024.The 1-10 reverse split was announced on Wednesday, July 10th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did HOOKIPA Pharma IPO?

HOOKIPA Pharma (HOOK) raised $100 million in an IPO on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Kempen was co-manager.

How do I buy shares of HOOKIPA Pharma?

Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of HOOKIPA Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HOOKIPA Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Pfizer (PFE), Advanced Micro Devices (AMD), Cabaletta Bio (CABA) and Novo Nordisk A/S (NVO).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 10/08/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HOOK
• CIK: 1760542
• Web: www.hookipapharma.com
• Phone: 431-890-6360
• Fax: 43-1890-636-0399
• Employees: 160
• Year Founded: 2011

Price Target and Rating

• Average Price Target for HOOKIPA Pharma: $4.50
• High Price Target: $7.00
• Low Price Target: $2.00
• Potential Upside/Downside: +403.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$43.50 million
• Net Margins: -785.66%
• Pretax Margin: -785.15%
• Return on Equity: -120.09%
• Return on Assets: -77.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.61
• Quick Ratio: 3.61

Sales & Book Value

• Annual Sales: $9.35 million
• Price / Sales: 1.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.25 per share
• Price / Book: 0.21

Miscellaneous

• Outstanding Shares: 12,189,000
• Free Float: 11,787,000
• Market Cap: $10.90 million
• Optionable: Optionable
• Beta: 1.04